Pratley RE, et al. - In patients with type 2 diabetes (T2D) aged 65 years or older, researchers outlined the risks of cardiovascular (CV) events and severe hypoglycemia with insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100). For this investigation, all randomized subjects (n=7,637, full analysis set) were seperated into 50 to 64 years (n= 3,682), 65 to 74 years (n=3,136) and ≥75 years (n=819). According to findings, higher risks of CV death, all-cause mortality, and serious adverse events (SAEs), with trends for higher risks of major adverse cardiovascular events (MACE) and severe hypoglycemia were seen relative to increasing age, after adjustment for baseline differences. The effects on MACE, all-cause mortality and severe hypoglycemia were comparable across age groups of degludec vs glargine U100, signifying that both the risk of MACE and all-cause mortality is comparable while the risk of severe hypoglycemia is reduced with degludec, without regard to age. Evidence is only definite until the age of 74.